Dependence Receptors and Leukemia

Acute Lymphoblastic Leukemia Clinical Trial

Official title:

Dependence Receptors in Childhood Acute Leukemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03278145
• Other study ID #: 69HCL16_0806
• Status: Not yet recruiting
• Phase: N/A
• First received: September 8, 2017
• Last updated: September 11, 2017
• Start date: November 2017
• Est. completion date: November 2019

Study information

• Verified date: September 2017
• Source: Hospices Civils de Lyon
• Contact: Carine HALFON-DOMENECH, M.D, PhD
• Phone: 04 69 16 65 67
• Email: carine.halfon-domenech[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Acute leukaemias (AL) are the first cause of cancer in children, with a majority of B acute lymphoblastic leukemia (ALL). Some of the processes causing leukemogenesis are already identified and well characterized in some AL subtypes such as translocation t (12; 21) of good prognosis in ALL. However, translocations are not sufficient to explain all the different processes of leukemogenesis, and other processes such as genetic / epigenetic mutations leading to oncogene activation / inhibition of tumor suppressor genes are the object research. Among the latter, mutations in tumor suppressor genes such as DCC (Deleted in Colorectal Cancer) have recently been identified in solid cancers, such as in hemopathies. This gene was subsequently characterized as encoding a "dependence receptor" specifically binding to its Netrin-1 ligand.

Dependence receptors (RDs) are transmembrane receptors that cause cell death in the absence of their ligand. RD decreases tumor progression and overexpression of their ligands is observed in many cancers, such as B lymphomatous hemopathies in adults. Inhibition of the RD-ligand interaction constitutes a new and original therapeutic target in oncology.

The aim of this study is to investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse in patients aged 1 to 18 years, and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: November 2019
• Est. primary completion date: May 2019
• Gender: All
• Age group: 1 Year to 18 Years

Eligibility

Inclusion Criteria:

• aged between 1 and 18 years

• taken care of at the Institute of Hematology and Pediatric Oncology (Service of Professor Yves Bertrand, IHOPe)

• for acute lymphoblastic or myeloblastic leukemia

• initial diagnosis or relapse

• who do not have a vital emergency criterion at the time of taking care (see exclusion criteria)

• affiliated to a social security scheme (100% assumed)

• after signing the informed consent of the holders of parental authority

Exclusion Criteria:

• less than 1 year, or more than 18 years to diagnosis

• with chronic leukemia

• severe anemia at diagnosis (hemoglobin <40g / l), or a state of shock whatever the cause (infectious, cardiogenic, hypovolemic)

Related Conditions & MeSH terms

• Acute Disease
• Acute Leukemia
• Acute Lymphoblastic Leukemia
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Genetic:
• Genetic analyses
Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.

Locations

Country	Name	City	State
France	Institut d'Hématologie et d'Oncologie Pédiatrique	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection of specific labeling of the DCC-dependent receptor on the surface of leukemic cells	Primary endpoint: presence of specific labeling of the DCC-dependent receptor on the surface of leukemic cells that will be detectable in flow cytometry.; This marking will be both qualitative (positive signal = presence of the receptor, absence of signal = absence of the receptor), and quantitative (percentage of expression of the receptor on the surface of the cells).	Maximum 4 months (sampling at the time of diagnosis / relapse and remission)